Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | DRD5 | P21918 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | BAD | Q92934 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8078647 | 0.87 | DRD2 (0.32) | DRD2DRD1DRD5DRD3 | |
| SCHEMBL1615172 | 0.87 | DRD2 (0.35) | DRD2DRD1DRD5DRD3 | |
| SCHEMBL116183 | 0.81 | DRD2 (0.42) | DRD2DRD1DRD5DRD3BCL2L1 | |
| SCHEMBL8411757 | 0.81 | ALDH1A1 (0.39) | DRD2DRD1DRD5DRD3BCL2L1 | |
| SCHEMBL3159469 | 0.79 | DRD2 (0.33) | DRD2DRD1DRD5DRD3 | |
| SCHEMBL6712754 | 0.78 | — | — | |
| SCHEMBL17674771 | 0.78 | CA1 (0.33) | DRD2DRD1DRD5DRD3CA1 | |
| SCHEMBL3164236 | 0.76 | DRD2 (0.35) | DRD2DRD1DRD5DRD3 | |
| Ammonia Solution, Strong SCHEMBL1871983 | 0.75 | MAOA (0.37) | DRD2DRD1DRD5DRD3 | |
| SCHEMBL15405879 | 0.74 | PNMT (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572676-A4 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RES INST INC (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1572676-A2 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | Walker Cancer Research Institute, Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| US-6767919-B2 | 1-(N,N-DIALKYLAMINOALKYL)-4-SILYLOXYTHIOXANTHONE DERIVATIVES; ADMINISTERED IN NONTOXIC, PROTO-DRUG FORM; TIME DELAY ALLOWS FOR DIFFERENTIAL CONCENTRATION IN TARGET TISSUES OR CELLS; ACTIVATED BY DRUG | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-07-27 | — | — | US | claimed |
| WO-2004058143-A2 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RESEARCH INSTITUTE, INC. (US) | 2004-07-15 | — | — | WO | claimed |
| US-20040116508-A1 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-06-17 | — | — | US | claimed |
| EP-1572676-A4 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RES INST INC (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1572676-A2 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | Walker Cancer Research Institute, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040192578-A1 | High specificity anticancer drug design process | WALKER EVAN HARRIS (US) | 2004-09-30 | — | — | US | disclosed |
| US-6767919-B2 | 1-(N,N-DIALKYLAMINOALKYL)-4-SILYLOXYTHIOXANTHONE DERIVATIVES; ADMINISTERED IN NONTOXIC, PROTO-DRUG FORM; TIME DELAY ALLOWS FOR DIFFERENTIAL CONCENTRATION IN TARGET TISSUES OR CELLS; ACTIVATED BY DRUG | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-07-27 | — | — | US | disclosed |
| WO-2004058143-A2 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RESEARCH INSTITUTE, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040116508-A1 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192578-A1 | High specificity anticancer drug design process | MCL1, ABCG2, TP53 | DRD2 3833/4885DRD1 3559/4885DRD5 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.